Clinical Trial 20964

Cancer Type: Multiple
Study Type: Treatment
NCT#: NCT04579380

Phase: Phase II
Principal Investigator: Soliman, Hatem

Call 813-745-6100
or 1-800-679-0775 Learn More

Overview

Study Title

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Summary

This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get a drug called fulvestrant. The trial will also look at what side effects happen. A side effect is anything a drug does besides treating cancer.

Objective

1. To evaluate the antitumor activity of tucatinib given in combination with trastuzumab in subjects with previously treated, locally-advanced unresectable or metastatic HER2 overexpressing/amplified or mutated solid tumors 2. To evaluate the safety and tolerability of tucatinib given in combination with trastuzumab with or without fulvestrant

Treatments

Therapies

Chemotherapy (NOS); Therapy (NOS)

Medications

Faslodex (fulvestrant); Herceptin (Trastuzumab); Trastuzumab (); Tucatinib (); fulvestrant (); rhuMAb HER2 (Trastuzumab)

Inclusion Criteria

Histologically or cytologically confirmed diagnosis of locally-advanced unresectable or metastatic solid tumor, including primary brain tumors

Participants with non-squamous NSCLC must have progressed during or after standard treatment or for which no standard treatment is available

Participants with other disease types must have progressed during or after ≥1 prior line of systemic therapy for locally-advanced unresectable or metastatic disease

Disease progression during or after, or intolerance of, the most recent line of systemic therapy Disease demonstrating HER2 alterations (overexpression/amplification or HER2 activating mutations), as determined by local or central testing processed in a Clinical Laboratory Improvement Amendments (CLIA)- or International Organization for Standardization (ISO) accredited laboratory, according to one of the following: HER2 overexpression/amplification from fresh or archival tumor tissue or blood, Known activating HER2 mutations detected in fresh or archival tumor tissue or blood

Have measurable disease per RECIST v1.1 criteria according to investigator assessment

Have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Other criteria apply

Exclusion Criteria

Participants with breast cancer, gastric or gastroesophageal junction adenocarcinoma, or CRC whose disease shows HER2 amplification/overexpression.

Previous treatment with HER2-directed therapy; participants with uterine serous carcinoma or HER2-mutated gastric or gastroesophageal junction adenocarcinoma without HER2-overexpression/amplification may have received prior trastuzumab

Known hypersensitivity to any component of the drug formulation of tucatinib or trastuzumab (drug substance, excipients, murine proteins), or any component of the drug formulation of fulvestrant in participants with HR+ HER2-mutated breast cancer

History of exposure to a 360 mg/m² doxorubicin-equivalent or >720 mg/m^2 epirubicin-equivalent cumulative dose of anthracyclines

Treatment with any systemic anti-cancer therapy, radiation therapy, major surgery, or experimental agent within ≤3 weeks of first dose of study treatment or are currently participating in another interventional clinical trial.